Skip to main navigation

MoonLake

e: info@moonlaketx.com

About us
Science
Investor relations

Site - Main

About us
Science
Investor relations

e: info@moonlaketx.com

INVESTOR RELATIONS

Press Releases

Year

All News
2026
2025
2024
2023
2022
2021

Apr 3 2025

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

Read More +

Feb 26 2025

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

Read More +

Jan 8 2025

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

Read More +

Nov 13 2024

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

Read More +

Nov 7 2024

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

Read More +

Sep 9 2024

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

Read More +

Aug 7 2024

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11

Read More +

Jun 10 2024

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

Read More +

May 16 2024

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

Read More +

May 7 2024

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

Read More +

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Next page
Last page

Displaying 11 - 20 of 54

Site - Investor Tools

Contact Us

MoonLake Immunotherapeutics Dorfstrasse 29, 6300 Zug, Schweiz/Switzerland

e: info@moonlaketx.com
media: media@moonlaketx.com
IR: ir@moonlaketx.com

Quick Links

Home
About us
Team
Science
Pipeline

Therapeutic focus
Investor relations
Careers
Privacy policy

© 2026 - MoonLake Immunotherapeutics

Privacy Policy